Caris Life Sciences submitted an application to New York State Department of Health’s Clinical Laboratory Evaluation Program to authorize Caris Assure for specimens originating in the state. The review will be conducted by NYSDOH’s Wadsworth Center, marking the start of a formal authorization pathway. Caris Assure is described as a blood-based genomic profiling assay using circulating nucleic acids sequencing and whole-exome/whole-transcriptome analysis across 22,000 genes. Caris said the assay includes assessments for tumor alterations, clonal hematopoiesis, inherited variants, pharmacogenomic alterations, microsatellite instability, and tumor mutational burden. The filing underscores Caris’ focus on scaling molecular profiling services at the state-authorized level, following reported revenue momentum tied to its assay suite.